In the targeted therapy setting, Gray et al. demonstrated that treatment-naïve patients with advanced EGFR mutant NSCLC without evidence of plasma ctDNA at diagnosis had improved PFS when treated with osimertinib, likely related to lower tumour burden [92]. Here, EGFR is linked to neoplasm.